JP2010521476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521476A5 JP2010521476A5 JP2009553689A JP2009553689A JP2010521476A5 JP 2010521476 A5 JP2010521476 A5 JP 2010521476A5 JP 2009553689 A JP2009553689 A JP 2009553689A JP 2009553689 A JP2009553689 A JP 2009553689A JP 2010521476 A5 JP2010521476 A5 JP 2010521476A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hcv
- hydrogen
- inhibitor
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 41
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 12
- -1 hydroxy, benzyloxy Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 229940121649 protein inhibitor Drugs 0.000 claims 8
- 239000012268 protein inhibitor Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 3
- 108010036949 Cyclosporine Proteins 0.000 claims 3
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 3
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 3
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 3
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 3
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960001265 ciclosporin Drugs 0.000 claims 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 3
- 229930182912 cyclosporin Natural products 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 239000003001 serine protease inhibitor Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- 229940121759 Helicase inhibitor Drugs 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89488707P | 2007-03-14 | 2007-03-14 | |
| US60/894,887 | 2007-03-14 | ||
| US98947407P | 2007-11-21 | 2007-11-21 | |
| US60/989,474 | 2007-11-21 | ||
| PCT/US2008/055893 WO2008112473A1 (en) | 2007-03-14 | 2008-03-05 | Compounds for the treatment of hepatitis c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010521476A JP2010521476A (ja) | 2010-06-24 |
| JP2010521476A5 true JP2010521476A5 (enExample) | 2011-04-14 |
| JP5232178B2 JP5232178B2 (ja) | 2013-07-10 |
Family
ID=39477552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009553689A Expired - Fee Related JP5232178B2 (ja) | 2007-03-14 | 2008-03-05 | C型肝炎の治療のための化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7547690B2 (enExample) |
| EP (1) | EP2118109B1 (enExample) |
| JP (1) | JP5232178B2 (enExample) |
| KR (1) | KR20100015304A (enExample) |
| CN (1) | CN101657455B (enExample) |
| AR (1) | AR065772A1 (enExample) |
| AU (1) | AU2008226639B2 (enExample) |
| BR (1) | BRPI0808763A2 (enExample) |
| CA (1) | CA2681093A1 (enExample) |
| CL (1) | CL2008000751A1 (enExample) |
| CO (1) | CO6180426A2 (enExample) |
| EA (1) | EA016614B1 (enExample) |
| IL (1) | IL200905A0 (enExample) |
| MX (1) | MX2009009473A (enExample) |
| NZ (1) | NZ579342A (enExample) |
| PE (1) | PE20090648A1 (enExample) |
| TW (1) | TW200848058A (enExample) |
| WO (1) | WO2008112473A1 (enExample) |
| ZA (1) | ZA200906129B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| PL2209789T3 (pl) * | 2007-11-20 | 2012-04-30 | Bristol Myers Squibb Co | Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| AU2008339917B2 (en) | 2007-12-24 | 2013-02-07 | Tibotec Pharmaceuticals | Macrocyclic indoles as hepatitis C virus inhibitors |
| EP2280978B1 (en) * | 2008-03-27 | 2013-04-24 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| US8178523B2 (en) * | 2008-03-27 | 2012-05-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8138171B2 (en) * | 2008-03-27 | 2012-03-20 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| BR112012013765A2 (pt) | 2009-12-07 | 2016-04-26 | Targacept Inc | 3,6-diazabiciclo[3.1.1] heptanos como ligantes de receptor nicotínico neuronal de acetilcolina |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| WO2014011863A1 (en) * | 2012-07-12 | 2014-01-16 | Targacept, Inc. | Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane |
| AU2013290402A1 (en) * | 2012-07-18 | 2015-03-05 | Bristol-Myers Squibb Holdings Ireland | Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
| JP2019510020A (ja) | 2016-03-15 | 2019-04-11 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 害虫を防除するための置換スルホニルアミド類 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN110028510A (zh) * | 2019-05-22 | 2019-07-19 | 南京合巨药业有限公司 | 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法 |
| KR20220098170A (ko) | 2019-11-07 | 2022-07-11 | 바이엘 악티엔게젤샤프트 | 동물 해충 방제를 위한 치환된 술포닐 아미드 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005013922D1 (de) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2005298403A1 (en) | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN101490054B (zh) | 2006-05-25 | 2012-05-16 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
-
2008
- 2008-02-28 US US12/039,239 patent/US7547690B2/en active Active
- 2008-03-05 WO PCT/US2008/055893 patent/WO2008112473A1/en not_active Ceased
- 2008-03-05 KR KR1020097019018A patent/KR20100015304A/ko not_active Ceased
- 2008-03-05 AU AU2008226639A patent/AU2008226639B2/en not_active Ceased
- 2008-03-05 EA EA200901241A patent/EA016614B1/ru not_active IP Right Cessation
- 2008-03-05 BR BRPI0808763-6A patent/BRPI0808763A2/pt not_active IP Right Cessation
- 2008-03-05 JP JP2009553689A patent/JP5232178B2/ja not_active Expired - Fee Related
- 2008-03-05 CA CA002681093A patent/CA2681093A1/en not_active Abandoned
- 2008-03-05 MX MX2009009473A patent/MX2009009473A/es not_active Application Discontinuation
- 2008-03-05 CN CN200880008369XA patent/CN101657455B/zh not_active Expired - Fee Related
- 2008-03-05 NZ NZ579342A patent/NZ579342A/en not_active IP Right Cessation
- 2008-03-05 EP EP08743684.6A patent/EP2118109B1/en not_active Not-in-force
- 2008-03-13 TW TW097108906A patent/TW200848058A/zh unknown
- 2008-03-13 PE PE2008000473A patent/PE20090648A1/es not_active Application Discontinuation
- 2008-03-13 CL CL200800751A patent/CL2008000751A1/es unknown
- 2008-03-14 AR ARP080101085A patent/AR065772A1/es not_active Application Discontinuation
-
2009
- 2009-09-03 ZA ZA2009/06129A patent/ZA200906129B/en unknown
- 2009-09-10 CO CO09097263A patent/CO6180426A2/es active IP Right Grant
- 2009-09-13 IL IL200905A patent/IL200905A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010521476A5 (enExample) | ||
| JP2010515752A5 (enExample) | ||
| JP2010521481A5 (enExample) | ||
| JP2010521484A5 (enExample) | ||
| JP2010521483A5 (enExample) | ||
| HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
| US8426458B2 (en) | Hepatitis C Virus inhibitors | |
| US8420686B2 (en) | Linked diimidazole antivirals | |
| US8703938B2 (en) | Hepatitis C virus inhibitors | |
| JP2012504632A5 (enExample) | ||
| JP2010510234A5 (enExample) | ||
| US9060971B2 (en) | Combination pharmaceutical agents as inhibitors of HCV replication | |
| US8314135B2 (en) | Linked dibenzimidazole antivirals | |
| JP2012512169A5 (enExample) | ||
| JP2012504132A5 (enExample) | ||
| JP2011523651A5 (enExample) | ||
| JP2008530096A5 (enExample) | ||
| JP2011521965A5 (enExample) | ||
| MY146123A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same | |
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| JP2012504126A5 (enExample) | ||
| JP2012511004A5 (enExample) | ||
| JP2010508362A5 (enExample) | ||
| WO2004014313A3 (en) | Combination pharmaceutical agents as inhibitors of hcv replication | |
| JP2010509376A5 (enExample) |